IDN-Level Data
That's Timely and
Transparent
As integrated delivery networks (IDNs) continue to grow in size and scope, it’s critical that pharma manufacturers target these key accounts, yet finding the right data to inform a robust IDN commercial strategy can seem like an insurmountable obstacle.
MMIT’s PULSE Analytics solution provides one of the most comprehensive and granular data sets to help pharma companies get the actionable insights they need to target these critical accounts.
PULSE Analytics enables pharma companies to:
- Understand product and competitor placement on pathways
- Understand if product placement matches the FDA label or is more restrictive
- Understand the structure and granular details of IDN customers
- Prioritize which IDNs to contract with and how by identifying key influencers
Learn More About PULSE Analytics Today
PULSE Analytics: Provider and Pathways Brochures
Download brochures to learn more about Provider Analytics:
PULSE Provider includes clinical pathway information for IDNs that create and maintain their own pathways.
PULSE Pathways includes data on third parties that develop pathways for IDNs and payers.
Consulting Services
MMIT and The Dedham Group have united to offer premier advisory services to oncology clients.
Our Solution,
By the Numbers
With our comprehensive data solution, you’ll gain insights into:
- 89 IDNs, community practices, health systems and cancer centers by region
- All third-party pathway organizations, representing 9,000 oncologists and 89 million payer medical lives
- 2,000-plus key decision makers across various tumor specialties and NCCN panel members/key opinion leaders
- 75+ organizations, representing Alternative Payment Model (APM) disease committee panel members and payer and provider organizational participants responsible for implementing and running analytics on various pathways and APMs
- Brand-specific management data across active oncology indications and over 150 brands for each pathway
- Which IDNs have URAC- and ACHC-accredited internal dispensing and/or specialty pharmacy capabilities
- Which IDNs use internally developed vs third-party clinical pathways, and what pathway management tools are implemented
Gain Insights into Pathways, Providers and Alternative Payment Models
PULSE Analytics provides actionable data and valuable insights on an intuitive, user-friendly platform.
PULSE Provider offers indication-specific insights on internally developed pathways and key provider account profiles, and includes a decision maker map and regional footprint.
PULSE Pathways offers indication-specific insights on third-party clinical pathway adoption, institution protocols, brand positioning, key influencers and adoption/mix.
PULSE APM can help you evaluate the impact of emerging oncology payment models, program structure, financial incentives / penalties, and indication-specific value drivers
Additional Resources
Thought Leadership
Pathway or Perish: The Two-Pronged Hurdle to Ensuring Access in Oncology
Without an accurate understanding of the existing barriers, manufacturers could be spinning their wheels in the field or, what’s worse, making unnecessary rebate payments to payers.
READ FULL ARTICLE
Thought Leadership
The Power of Partnerships: Why Pharma Needs to Redefine its Role With IDNs
As IDNs continue to expand their reach and influence, it’s time for pharma companies to rethink their one-size-fits-all approach to IDN engagement. Here’s how.
READ FULL ARTICLERelated Solutions to Support Your Strategy
MMIT offers a variety of payer account and contact intelligence solutions. Learn more about them below.